Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
China channel feed
Chen Yu jumps ship from Vivo Capital and goes large, allying with The Column Group on an inaugural $824M biotech crossover fund
5 years ago
Financing
Eli Lilly seeds a well-connected China neuro startup with drugs aiming at where Biogen, Voyager missed
5 years ago
Deals
Trans-Pacific bispecific player caps 'very challenging' pandemic year with $120M to gain a foothold among the giants
5 years ago
Roger Perlmutter’s latest ‘retirement’ gig opens a door to the bustling China biotech scene
5 years ago
Bioregnum
Opinion
China's YishengBio chronicles comeback story in Hong Kong IPO while plotting big moves in infectious diseases, cancer
5 years ago
Financing
Angling Pfizer, AstraZeneca jumps into commercial PD-(L)1 fight in China
5 years ago
Deals
Pharma
Six years separated from a rabies vaccine scandal, China’s YishengBio grabs $130M to go big in infectious diseases, cancer
5 years ago
Financing
A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal
5 years ago
Deals
Months after shocking house arrest, Legend co-founder Frank Zhang is out on bail — though the CAR-T player has moved on
5 years ago
People
A synthetic lethality player emerges in China, armed with lessons on undruggable oncogene from Nobel laureate's lab
5 years ago
Financing
Startups
Innovent and Lilly win second China OK for Tyvyt in frontline NSCLC, ramping up pressure on king Keytruda
5 years ago
FDA+
Nasdaq rings in its first biotech IPOs of 2021: a CAR-T specialist from China, a cancer portfolio play, and a SPAC
5 years ago
Financing
Cell/Gene Tx
Fast-expanding Shanghai Pharma breaks ground on $1.8B biotech park focused on next-gen R&D, antibody production
5 years ago
Manufacturing
Months after striking SHP2 deal with AbbVie, Jacobio pulls in $174M+ from Hong Kong IPO
5 years ago
Financing
A booming market propels China CRO to a $100M raise. Is an IPO next?
5 years ago
Financing
Outsourcing
AbbVie's Covid-19 antibody partner wraps $221M Hong Kong IPO
5 years ago
Financing
Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland
5 years ago
Deals
'Scale and speed': Hillhouse puts its weight behind China startup eyeing cutting-edge tech from around the world
5 years ago
Startups
With plans to bring surufatinib stateside, Chi-Med vastly scales up manufacturing with new Chinese plant
5 years ago
Manufacturing
GlaxoSmithKline R&D vet Min Li nabs $100M to launch a Bob Nelsen-backed startup focused on China’s burgeoning neuro market
5 years ago
Financing
Startups
China opens the door for biotech investors in Hong Kong to buy Shanghai stocks, and vice versa
5 years ago
Financing
Plot thickens around Legend Biotech, GenScript with founder Frank Zhang's arrest
5 years ago
People
Pfizer hands LianBio $70M to tag along Perceptive's China play, with an eye to beefing up regional portfolio
5 years ago
Deals
Here's a $200M China startup idea — if you can read beyond the big words
5 years ago
Financing
Startups
First page
Previous page
14
15
16
17
18
19
20
Next page
Last page